Research: Direct Factor X Inhibitor vs Low-Molecular-Weight Heparin for Cancer-Associated VTE 1 Jan, 2018 | 12:12h | UTC Industry-funded trial finds a direct factor X inhibitor noninferior to a low-molecular-weight heparin for cancer-associated VTE – ACP Internist (free) See original article in the NEJM (free)